UY36195A - Amidas de benzoxazinona como reguladores del receptor mineralocorticoide - Google Patents

Amidas de benzoxazinona como reguladores del receptor mineralocorticoide

Info

Publication number
UY36195A
UY36195A UY0001036195A UY36195A UY36195A UY 36195 A UY36195 A UY 36195A UY 0001036195 A UY0001036195 A UY 0001036195A UY 36195 A UY36195 A UY 36195A UY 36195 A UY36195 A UY 36195A
Authority
UY
Uruguay
Prior art keywords
mineralocorticoid
benzoxazinona
amidas
regulators
receiver
Prior art date
Application number
UY0001036195A
Other languages
English (en)
Spanish (es)
Inventor
Gavin O'mahony
Kossenjans Michael
Edman Karl
Kajanus Johan
Cornwall Philip
Turner Andrew
Carl Anders Hogner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY36195A publication Critical patent/UY36195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UY0001036195A 2014-06-30 2015-06-26 Amidas de benzoxazinona como reguladores del receptor mineralocorticoide UY36195A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30

Publications (1)

Publication Number Publication Date
UY36195A true UY36195A (es) 2016-01-08

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036195A UY36195A (es) 2014-06-30 2015-06-26 Amidas de benzoxazinona como reguladores del receptor mineralocorticoide

Country Status (26)

Country Link
US (2) US10017502B2 (2)
EP (1) EP3160948B1 (2)
JP (1) JP6368383B2 (2)
KR (1) KR102012222B1 (2)
CN (1) CN106536491B (2)
AR (1) AR101036A1 (2)
AU (1) AU2015282450C1 (2)
CA (1) CA2953655C (2)
CY (1) CY1121596T1 (2)
DK (1) DK3160948T3 (2)
EA (1) EA029518B1 (2)
ES (1) ES2707726T3 (2)
HR (1) HRP20190147T1 (2)
HU (1) HUE042370T2 (2)
LT (1) LT3160948T (2)
ME (1) ME03316B (2)
MX (1) MX367404B (2)
PL (1) PL3160948T3 (2)
PT (1) PT3160948T (2)
RS (1) RS58274B1 (2)
SI (1) SI3160948T1 (2)
SM (1) SMT201900039T1 (2)
TR (1) TR201900659T4 (2)
TW (1) TWI677498B (2)
UY (1) UY36195A (2)
WO (1) WO2016001631A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367404B (es) * 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
WO2021037400A1 (en) * 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
CA3222502A1 (en) 2021-06-15 2022-12-22 Lingyun Wu Benzoxazinone derivatives
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
CR20250112A (es) 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
CN120344508A (zh) * 2022-12-15 2025-07-18 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528335A (ja) * 2001-04-23 2004-09-16 アストラゼネカ アクチボラグ 血管新生の治療に使用のベンゾオキサジノン誘導体
AU2003303231A1 (en) * 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
BRPI0513119A (pt) * 2004-07-14 2008-04-29 Ligand Pharm Inc compostos e métodos modulares de receptores intracelulares
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
CA2635541A1 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
SI2089367T1 (sl) 2006-10-31 2012-02-29 Pfizer Prod Inc Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
WO2008118319A2 (en) 2007-03-23 2008-10-02 Merck & Co., Inc. Mineralocorticoid receptor modulators
CN101679243B (zh) 2007-04-09 2012-09-26 第一三共株式会社 吡咯衍生物的阻转异构体
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
WO2009154557A1 (en) * 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
AU2010222902B2 (en) 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
US20120022058A1 (en) 2009-04-10 2012-01-26 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
CN102906495B (zh) 2010-05-11 2016-08-24 皇家飞利浦电子股份有限公司 照明模块
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
EP2638012A1 (en) 2010-11-10 2013-09-18 Boehringer Ingelheim International GmbH Pyridyl ureas as mineralocorticoid receptor antagonists
MX367404B (es) * 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.

Also Published As

Publication number Publication date
TR201900659T4 (tr) 2019-02-21
ME03316B (me) 2019-10-20
ES2707726T3 (es) 2019-04-04
US9394291B2 (en) 2016-07-19
EA201790046A1 (ru) 2017-08-31
CN106536491A (zh) 2017-03-22
KR20170021883A (ko) 2017-02-28
EA029518B1 (ru) 2018-04-30
MX367404B (es) 2019-08-20
EP3160948A1 (en) 2017-05-03
US20170217945A1 (en) 2017-08-03
AU2015282450A1 (en) 2017-02-02
CY1121596T1 (el) 2020-05-29
KR102012222B1 (ko) 2019-10-21
JP6368383B2 (ja) 2018-08-01
RS58274B1 (sr) 2019-03-29
HRP20190147T1 (hr) 2019-03-22
SMT201900039T1 (it) 2019-02-28
PL3160948T3 (pl) 2019-04-30
AU2015282450B2 (en) 2018-05-10
AU2015282450C1 (en) 2018-09-20
US10017502B2 (en) 2018-07-10
JP2017522300A (ja) 2017-08-10
SI3160948T1 (sl) 2020-06-30
CN106536491B (zh) 2018-12-18
US20150376170A1 (en) 2015-12-31
PT3160948T (pt) 2019-02-01
MX2017000183A (es) 2017-04-25
TWI677498B (zh) 2019-11-21
CA2953655A1 (en) 2016-01-07
TW201613909A (en) 2016-04-16
AR101036A1 (es) 2016-11-16
HUE042370T2 (hu) 2019-06-28
LT3160948T (lt) 2019-02-11
WO2016001631A1 (en) 2016-01-07
CA2953655C (en) 2020-05-12
EP3160948B1 (en) 2018-10-24
DK3160948T3 (en) 2019-02-18

Similar Documents

Publication Publication Date Title
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
CR20160565A (es) Derivados de naftiridinadiona
MX377506B (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204